logo-loader
viewNetscientific PLC

NetScientific appoints new scientific advisory board

The board comprises of distinguished clinicians and bioengineers.

White blood celll
"We are thrilled to have attracted some of the world's leading experts."

Healthcare technology group NetScientific plc (LON:NSCI) has made a number of appointments to its newly formed scientific advisory board (SAB) at its portfolio company Vortex Biosciences.

The board comprises of distinguished clinicians and bioengineers in the field of oncology and circulating tumour cells (CTC).

It will provide strategic guidance in decision-making to support the development and commercialization of Vortex's CTC enrichment system for both the research and diagnostic markets.

"We are thrilled to have attracted some of the world's leading experts in circulating tumor cells, oncology, clinical trials and microfluidics to help us define our clinical strategy as we commercialize our next generation CTC enrichment system, the VTX-1," said Vortex chief executive Gene Walther.

"The formation of our SAB serves as an endorsement of the scientific and clinical enthusiasm for the Vortex technology."

Quick facts: Netscientific PLC

Price: 6 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read